Przegląd Dermatologiczny

Abstract

2/2021 vol. 108
Original paper

Salivary biomarkers in patients with psoriasis – a meta-analysis

  1. Fertility and Infertility Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
  2. Medical Biology Research Centre, Kermanshah University of Medical Sciences, Kermanshah, Iran
  3. Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
Dermatol Rev/Przegl Dermatol 2021, 108, 105-116
Online publish date: 2021/06/28
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

Psoriasis is a chronic, inflammatory cutaneous disease with an unclear aetiology. Several biomarkers have been investigated for their significance in clinical practice. Objective. This meta-analysis aimed to evaluate the salivary biomarkers in psoriatic patients compared to controls.

Material and methods

The PubMed, Scopus, Web of Science, and Cochrane Library databases were searched from the beginning of each database. The mean differences (MDs) or odds ratios (ORs) with 95% confidence intervals (CIs) in all studies were analysed using Review Manager 5.3 software.

Results

Fourteen studies were analysed in the meta-analysis. Investigating salivary α-amylase, cortisol, IgA, interleukin-1b, candida incidence, antipyrine clearance, sodium, potassium, chloride, and flow rate levels, there was a significant difference between psoriatic patients and controls in α-amylase (MD = 12.69 IU/ml), interleukin-1b (MD = 1.60 pg/ml), and candida incidence (OR = 7.64), respectively. Some salivary biomarkers such as α-amylase, interleukin-1b, and candida incidence were significantly higher in the patients with psoriasis than in the controls.

Conclusions

The results indicate that saliva analysis is a valid noninvasive tool which may be used to monitor inflammation in psoriasis.

Share
without publication fees
without publication fees